Refining the role of BRCA1 in combating oxidative stress

Breast Cancer Research

Volumn 15, Issue 6, 2013, Pages

  Marks, Jeffrey R ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; BRCA1 PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3; ANTIOXIDANT;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BREAST CANCER; CARCINOGENESIS; CONFORMATIONAL TRANSITION; DNA DAMAGE; DNA REPAIR; EPITHELIUM CELL; EXCISION REPAIR; FAMILIAL CANCER; GENE CONTROL; GENE MUTATION; GENOME; HOMOLOGOUS RECOMBINATION; HUMAN; MOLECULAR PATHOLOGY; OVARY CANCER; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANCREAS CANCER; POSITIVE FEEDBACK; SOMATIC MUTATION; STEM CELL; UBIQUITINATION; UTERINE TUBE; ANIMAL; CELL SURVIVAL; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; BRCA1 PROTEIN; CELL SURVIVAL; FEMALE; HUMANS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 84889562208     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3583     Document Type: Article

References (13)

1. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004, 10:2473-2481. 10.1158/1078-0432.CCR-1029-3, 15073127.
2. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 2011, 29:4373-4380. 10.1200/JCO.2010.33.6446, 3221522, 22010008.
3. Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A 2013, 110:17041-17046. 10.1073/pnas.1305170110, 24085845.
4. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009, 284:13291-13295. 10.1074/jbc.R900010200, 2679427, 19182219.
5. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008, 105:13568-13573. 10.1073/pnas.0806268105, 2533230, 18757741.
6. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, Rosen EM. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004, 64:7893-7909. 10.1158/0008-5472.CAN-04-1119, 15520196.
7. Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, Gauthier ML. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 2013, 210:1529-1544. 10.1084/jem.20121337, 23857982.
8. Saha T, Rih JK, Rosen EM. BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett 2009, 583:1535-1543. 10.1016/j.febslet.2009.04.005, 2744635, 19364506.
9. Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, Pavlides S, Lamb R, Sneddon S, Howell A, Sotgia F, Lisanti MP. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle 2012, 11:4402-4413. 10.4161/cc.22776, 3552923, 23172369.
10. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010, 70:7353-7359. 10.1158/0008-5472.CAN-10-1012, 2948578, 20858716.
11. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN, Zhang DD, Xia B. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 2012, 32:1506-1517. 10.1128/MCB.06271-11, 3318596, 22331464.
12. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013, 3:228. 3769628, 24062981.
13. Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, Nguyen H, Thomas CE, Iversen ES, Marsillac S, Karchin R, Koomen J, Monteiro AN. Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal 2012, 5:rs6.